ArticleInternational ophthalmology2025
Evaluation of the choroidal vascularity index and choroidal thickness in patients with systemic sclerosis.
Article in International ophthalmology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeTo evaluate the choroidal structural components using central macular thickness (CMT), choroidal thickness (CT) and the choroidal vascular index (CVI) and compare the results between patients with systemic sclerosis (SSc), causing both fibrotic and angiopathic changes in tissues and healthy controls.
methodsThis prospective comparative study evaluated 22 patients with SSc (SSc group). The patients' choroidal thickness, CVI and choroidal area (CA) were compared with 21 healthy controls (control group). The patients' nailfold videocapillaroscopy (NVC) and modified Rodnan skin score (mRss) were evaluated by expert rheumatologists. In addition, the relationships between choroidal findings and NVC and mRss were assessed.
resultsThe central macular thickness in the SSc and control groups was 269.47 ± 26.78 µm and 261.19 ± 17.09 µm, respectively (p = 0.093). The subfoveal choroidal thickness was 295.38 ± 33.70 μm and 322.16 ± 70.24 μm, respectively (p = 0.026); the temporal choroidal thickness was 246.77 ± 21.83 μm and 265.26 ± 52.34 μm, respectively (p = 0.034); and the nasal choroidal thickness was 135.36 ± 28.10 μm and 158.88 ± 49.16 μm, respectively (p = 0.008). Total CA of 1.5 mm region centered on the fovea was 0.49 ± 0.08 mm
conclusionThis study found that choroidal thickness and CVI decreased in SSc patients. A decrease in CVI may be an indicator of damage, especially in luminal structures.
Indexed as
Identifiers
40338367What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.